Invesaro

Stocks Comparison

Abbott Laboratories vs ELI LILLY: revenue, profit, margins and growth compared

Abbott Laboratories brought in $44.3B of revenue in fiscal 2025, ELI LILLY $65.2B in fiscal 2025. Revenue changed by +5.7% at Abbott Laboratories and +44.7% at ELI LILLY on the year before, so ELI LILLY grew faster. Abbott Laboratories kept 14.7% of its revenue as net profit, ELI LILLY 31.7%.

Side by side, latest fiscal year

ABTLLY
Fiscal year endedFY2025 (December 31, 2025)FY2025 (December 31, 2025)
Revenue$44.3B$65.2B
Revenue growth+5.7%+44.7%
Net income$6.5B$20.6B
Net margin14.7%31.7%
Free cash flow$7.4Bn/a
Free cash flow margin16.7%n/a
Earnings per share (diluted)$3.72$22.95
Cash$8.5B$7.3B
Debt$12.9B$40.9B
Price to earnings27.251.6
Market value$175.3B$1.11T
Dividend yield2.37%0.53%
Rank by revenue in sector#18 of 523 · Health care#11 of 523 · Health care

Over the years

Revenue
ABT FY2018: $30.6BABT FY2019: $31.9BABT FY2020: $34.6BABT FY2021: $43.1BABT FY2022: $43.7BABT FY2023: $40.1BABT FY2024: $42BABT FY2025: $44.3BLLY FY2018: $21.5BLLY FY2019: $22.3BLLY FY2020: $24.5BLLY FY2021: $28.3BLLY FY2022: $28.5BLLY FY2023: $34.1BLLY FY2024: $45BLLY FY2025: $65.2BFY18FY19FY20FY21FY22FY23FY24FY25
ABT $44.3BLLY $65.2B
Net income
ABT FY2018: $2.4BABT FY2019: $3.7BABT FY2020: $4.5BABT FY2021: $7.1BABT FY2022: $6.9BABT FY2023: $5.7BABT FY2024: $13.4BABT FY2025: $6.5BLLY FY2018: $3.2BLLY FY2019: $8.3BLLY FY2020: $6.2BLLY FY2021: $5.6BLLY FY2022: $6.2BLLY FY2023: $5.2BLLY FY2024: $10.6BLLY FY2025: $20.6BFY18FY19FY20FY21FY22FY23FY24FY25
ABT $6.5BLLY $20.6B
Net margin
ABT FY2018: 7.7%ABT FY2019: 11.6%ABT FY2020: 13.0%ABT FY2021: 16.4%ABT FY2022: 15.9%ABT FY2023: 14.3%ABT FY2024: 31.9%ABT FY2025: 14.7%LLY FY2018: 15.0%LLY FY2019: 37.3%LLY FY2020: 25.2%LLY FY2021: 19.7%LLY FY2022: 21.9%LLY FY2023: 15.4%LLY FY2024: 23.5%LLY FY2025: 31.7%FY18FY19FY20FY21FY22FY23FY24FY25
ABT 14.7%LLY 31.7%
Revenue growth
ABT FY2019: +4.3%ABT FY2020: +8.5%ABT FY2021: +24.5%ABT FY2022: +1.3%ABT FY2023: -8.1%ABT FY2024: +4.6%ABT FY2025: +5.7%LLY FY2019: +3.8%LLY FY2020: +9.9%LLY FY2021: +15.4%LLY FY2022: +0.8%LLY FY2023: +19.6%LLY FY2024: +32.0%LLY FY2025: +44.7%FY19FY20FY21FY22FY23FY24FY25
ABT +5.7%LLY +44.7%
Free cash flow
ABT FY2018: $4.9BABT FY2019: $4.5BABT FY2020: $5.7BABT FY2021: $8.6BABT FY2022: $7.8BABT FY2023: $5.1BABT FY2024: $6.4BABT FY2025: $7.4BFY18FY19FY20FY21FY22FY23FY24FY25
ABT $7.4BLLY

Fiscal years as each company reports them; the two may end in different months.

Questions about Abbott Laboratories and ELI LILLY

Which is bigger by revenue, Abbott Laboratories or ELI LILLY?

ELI LILLY is bigger by revenue: $65.2B in fiscal 2025, against $44.3B for Abbott Laboratories in fiscal 2025.

Which keeps more of its revenue as profit, Abbott Laboratories or ELI LILLY?

Abbott Laboratories had a net margin of 14.7% in fiscal 2025; ELI LILLY had 31.7% in fiscal 2025.

Which grew revenue faster, Abbott Laboratories or ELI LILLY?

In their latest fiscal years revenue changed by +5.7% at Abbott Laboratories and +44.7% at ELI LILLY.

Where do these numbers come from?

From the annual reports each company files with the SEC (10-K, or 20-F and 40-F for foreign companies), read from their XBRL data. Margins and growth are simple arithmetic on those figures. Nothing here is a recommendation.

More comparisons

Compare more companies